Table 1 Baseline demographic and patient characteristics
Parameter | Statistics | |
|---|---|---|
Not hospitalized at start of the open-label phase | Hospitalized at start of the open-label phase | |
Age, years | ||
n | 646 | 382 |
Mean (SD) | 37.8 (11.0) | 37.3 (10.9) |
Median (range) | 38.0 (18.0; 76.0) | 36.0 (18.0; 66.0) |
Age groups, n (%) | ||
18 to < 35 | 278 (43.0) | 169 (44.2) |
35 to < 55 | 322 (49.8) | 191 (50.0) |
≥ 55 | 46 (7.1) | 22 (5.8) |
Gender, n (%) | ||
Female | 254 (39.3) | 165 (43.2) |
Male | 392 (60.7) | 217 (56.8) |
Schizophrenia duration, n (%) | ||
0 to < 4 years | 166 (25.7) | 92 (24.1) |
4 to < 10 years | 189 (29.3) | 121 (31.7) |
≥ 10 years (includes 2 missing) | 291 (45.0) | 168 (44.0) |
Study country, n (%) | ||
US | 198 (30.7) | 34 (8.9) |
Non-US | 448 (69.3) | 348 (91.1) |
Remaining in trial, n (%) | ||
Week 1 | 646 (100.0) | 382 (100.0) |
Week 4 | 646 (100.0) | 382 (100.0) |
Week 8 | 563 (87.2) | 315 (82.5) |
Week 12 | 522 (80.8) | 286 (74.9) |
Week 16 | 490 (75.9) | 263 (68.8) |
Week 20 | 473 (73.2) | 252 (66.0) |
Week 24 | 446 (69.0) | 242 (63.4) |
Week 28 | 414 (64.1) | 229 (59.9) |
Week 32 | 400 (61.9) | 222 (58.1) |
Week 36 | 379 (58.70 | 210 (55.0) |
Week 40 | 365 (56.5) | 202 (52.9) |
Week 44 | 354 (54.8) | 193 (50.5) |
Week 48 | 335 (51.9) | 189 (49.5) |
Week 52 | 319 (49.4) | 187 (49.0) |